Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China

References

• Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401.
   PubMed Web of Science ®Google Scholar
• Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the children's oncology group TARGET project. Blood. 2013;121(3):485–488.
   PubMed Web of Science ®Google Scholar
• Den BML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125–134.
   PubMedGoogle Scholar
• Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the children's oncology group. Blood. 2018;132(8):815–824.
   PubMed Web of Science ®Google Scholar
• Cho H, Kim Y, Yoon JH, et al. Non-inferior long-term outcomes of adults with philadelphia chromosome-like acute lymphoblastic leukemia. Bone Marrow Transplant. 2021;56(8):1953–1963.
   PubMed Web of Science ®Google Scholar
• Kaczmarska A, Sliwa P, Zawitkowska J, et al. Genomic analyses of pediatric acute lymphoblastic leukemia Ph þ and Ph-like-recent progress in treatment. Int J Mol Sci. 2021;22(12):6411.
   PubMedGoogle Scholar
• Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019;134(16):1351–1355.
   PubMed Web of Science ®Google Scholar
• Nardi V, Ku N, Frigault MJ, et al. Clinical response to larotrectinib in adult philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020;4(1):106–111.
   PubMed Web of Science ®Google Scholar
• Yenamandra AK, Kaviany S, Borinstein SC, et al. BCR-ABL1-like B-Lymphoblastic leukemia/lymphoma with FOXP1-ABL1 rearrangement: comprehensive laboratory identification allowing tyrosine kinase inhibitor use. Lab Med. 2019;50(4):401–405.
   PubMedGoogle Scholar
• Aldoss I, Kamal MO, Forman SJ, et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia: considerations for allogeneic hematopoietic cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2019;25(2):e41–e45.
   PubMedGoogle Scholar
• Zhang Y, Gao Y, Zhang H, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018;131(20):2256–2261.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Advani AS. Have any strategies in Ph-like ALL been shown to be effective. Best Pract Res Clin Haematol. 2021;34(1):101242.
   PubMedGoogle Scholar
• Freyer CW, Porter DL. Advances in CAR T therapy for hematologic malignancies. Pharmacotherapy. 2020;40(8):741–755.
   PubMed Web of Science ®Google Scholar
• Hua J, Qian W, Wu X, et al. Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells for a pediatric Ph-like B-ALL patient that relapsed after CART-Cell and Haplo-HSCT therapy: a case report and review of literature. Onco Targets Ther. 2020;13:2311–2317.
   PubMed Web of Science ®Google Scholar
• Nie Y, Lu W, Chen D, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020;8:18.
   PubMedGoogle Scholar
• Zhang XH, Chen J, Han MZ, et al. The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.
   PubMed Web of Science ®Google Scholar
• Zhou B, Chu X, Tian H, et al. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: a 10-year retrospective study. Am J Hematol. 2021;96(11):1461–1471.
   PubMedGoogle Scholar
• Tang S, Shen H, Qu C, et al. Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes. Bone Marrow Transplant. 2019;54(2):236–243.
   PubMedGoogle Scholar
• Gu B, Shi BY, Zhang X, et al. Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells. Bone Marrow Transplant. 2021;56(1):91–100.
   PubMedGoogle Scholar
• Yang F, Zhang J, Zhang X, et al. Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells. Onco Targets Ther. 2019;12:2187–2191.
   PubMed Web of Science ®Google Scholar
• Zhou B, Wang T, Lei L, et al. Prognostic values of increased B7 family proteins in haploidentical hematopoietic stem cell transplantation patients with aGVHD. Int J Hematol. 2019;109(4):451–462.
   PubMedGoogle Scholar
• Gu B, Wu X, Chen G, et al. Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Res. 2017;59:41–46.
   PubMedGoogle Scholar
• Chen J, Wang RX, Chen F, et al. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplant. 2014;49(2):206–211.
   PubMed Web of Science ®Google Scholar
• Hu Y, He H, Lu J, et al. E2A-PBX1 exhibited a promising prognosis in pediatric acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol. OTT. 2016;ume 9:7219–7225.
   Google Scholar
• Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(9):1079–1109.
   PubMedGoogle Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312–5321.
   PubMed Web of Science ®Google Scholar
• Madzio J, Pastorczak A, Sedek L, et al. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2019;58(9):619–626.
   PubMedGoogle Scholar
• Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572–581.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Messina M, Della SI, et al. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica. 2021;106(6):1559–1568.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–1015.
   PubMed Web of Science ®Google Scholar
• Shah BD, Bishop MR, Oluwole OO, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11–22.
   PubMed Web of Science ®Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
   PubMed Web of Science ®Google Scholar
• El FR, Savani B, Mohty M, et al. Hematopoietic cell transplant consideration for Philadelphia chromosome-Like acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2020;26(1):e16–e20.
   PubMedGoogle Scholar